drugset / Trial / NCT01767493

Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients

NCT01767493

NaSingle-groupOpen-labelOther

Summary

The purpose of this study is to evaluate the feasibility of \[18F\]Florbetapir positron emission tomography (PET) for assessment of demyelination in the patients with relapsing remitting multiple sclerosis.

Timeline

Start
2012-11
Primary completion
2013-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject florbetapir F 18 Diagnostic / imaging agent

Indications